Proliverenol for liver fat and insulin resistance in type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional trial compares Proliverenol plus standard diabetes therapy versus standard therapy alone over 12 weeks in adults with type 2 diabetes. Participants will undergo blood tests and liver assessments to measure changes in liver fat and insulin resistance. Eligibility includes adults 30–65 with type 2 diabetes, specific liver fat or CAP-based criteria, and stable diabetes treatment. The goal is to see if Proliverenol can improve metabolic parameters and liver health in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients diagnosed with Type 2 diabetes
* VAI values: women \> 0.705, men \> 1.48, or CAP values ≥ 236
* Ages 30-65 years
* Receiving standard Type 2 diabetes treatment for at least 3 months with HbA1c levels between 7% and 9.5%.
* Willing to participate in the study by signing an informed consent form.

Exclusion Criteria:

* Taking long-term steroid medication, either oral or systemic.
* Pregnant or breastfeeding women
* History of or currently suffering from an autoimmune disease
* History of or previous infection with hepatitis B or C
* ALT/AST levels \> 2x ULN, eGFR \< 60, or unstable heart disease.
* Regular alcohol consumption

Where it's running

• University of Sriwijaya Palembang
  Palembang, South Sumatera, Indonesia Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes

  This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07896109

• RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes

  This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.

  Recruiting Bionime Corporation · Ulm, Baden-Wurttemberg · NCT07889388

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin

  This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).

  Recruiting at 8 sites Phase 3 Amgen · San Diego, California and 7 other locations · NCT07866066

• Switching from Semaglutide to CagriSema in Type 2 Diabetes

  This study tests whether people with type 2 diabetes can safely switch from branded semaglutide to CagriSema over about six months.

  Recruiting at 37 sites Phase 3 Novo Nordisk A/S · Gilbert, Arizona and 39 other locations · NCT07817251

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.